EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
about
Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Eph receptors as oncotargets.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
P2860
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
@en
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
@nl
type
label
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
@en
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
@nl
prefLabel
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
@en
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
@en
P2093
C Stylianou
G T Yarranton
J Woronicz
K J Miller
L T Cooper
M Lackmann
S Charmsaz
P2860
P2888
P304
P356
10.1038/LEU.2016.371
P577
2016-12-06T00:00:00Z